Markers of Monocyte Activation, Inflammation, and Microbial Translocation Are Associated with Liver Fibrosis in Alcohol Use Disorder

Background: The association between markers of inflammation (interleukin (IL)-6 and IL-10), monocyte activation (sCD163 and sCD14), and microbial translocation (lipopolysaccharide (LPS) and LPS binding protein) and liver fibrosis in patients with alcohol use disorder (AUD) and no overt liver disease is not well established. Methods: We studied patients admitted for treatment of AUD at two hospitals in Barcelona. Advanced liver fibrosis (ALF) was defined as FIB-4 > 3.25. Results: A total of 353 participants (76.3% male) were included and 94 (26.5%) had ALF. In adjusted correlation analyses, sCD163, sCD14, IL-6, IL-10, and LPS binding protein levels directly correlated with FIB-4 values (adjusted correlation coefficients 0.214, 0.452, 0.317, 0.204, and 0.171, respectively). However, LPS levels were inversely associated with FIB-4 (−0.283). All plasma marker levels in the highest quartile, except LPS, were associated with ALF (sCD163, sCD14, IL-6, IL-10, and LPS binding protein: adjusted odds ratio (aOR) 11.49 (95% confidence interval 6.42–20.56), 1.87 (1.11–3.16), 2.99 (1.79–5.01), 1.84 (1.11–3.16), and 2.13 (1.30–3.50), respectively). Conversely, LPS levels in the lowest quartile were associated with ALF (aOR 2.58 (1.48–4.58), p < 0.01). Conclusion: In AUD patients, plasma levels of the markers of inflammation, monocyte activation, and microbial translocation are associated with ALF.

Download Full-text

Association Analysis Between Genetic Variation in GATA Binding Protein 4 (GATA4) and Alcohol Use Disorder

Alcohol and Alcoholism ◽

10.1093/alcalc/agx120 ◽

2018 ◽

Vol 53 (4) ◽

pp. 361-367 ◽

Cited By ~ 1

Author(s):

Kelsey L Mauro ◽

Sarah G Helton ◽

Dan B Rosoff ◽

Audrey Luo ◽

Melanie Schwandt ◽

...

Keyword(s):

Genetic Variation ◽

Alcohol Use ◽

Association Analysis ◽

Alcohol Use Disorder ◽

Binding Protein

Download Full-text

Do serum markers of liver fibrosis vary by HCV infection in patients with alcohol use disorder?

Drug and Alcohol Dependence ◽

10.1016/j.drugalcdep.2018.04.008 ◽

2018 ◽

Vol 188 ◽

pp. 180-186 ◽

Cited By ~ 3

Author(s):

Arantza Sanvisens ◽

Alvaro Muñoz ◽

Ferran Bolao ◽

Paola Zuluaga ◽

Magí Farré ◽

...

Keyword(s):

Alcohol Use ◽

Liver Fibrosis ◽

Alcohol Use Disorder ◽

Serum Markers ◽

Hcv Infection

Download Full-text

Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder

Canadian Journal of Physiology and Pharmacology ◽

10.1139/cjpp-2019-0177 ◽

2019 ◽

Vol 97 (8) ◽

pp. 781-785 ◽

Cited By ~ 2

Author(s):

M.S. Zastrozhin ◽

V.Y. Skryabin ◽

V.V. Smirnov ◽

E.A. Grishina ◽

K.A. Ryzhikova ◽

...

Keyword(s):

Alcohol Use ◽

High Performance ◽

Alcohol Use Disorder ◽

Depressive Disorders ◽

Rating Scale ◽

Correlation Coefficients ◽

Inverse Correlation ◽

Efficacy And Safety ◽

Cyp2d6 Activity ◽

Scale Scores

The objective of the study was to investigate the effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder who received mirtazapine. The study included 109 Russian patients who received mirtazapine at a dose of 30.0 [15.0; 45.0] mg per day. Genotyping of CYP2D6*4 (1846G > A, rs3892097) was performed using real-time polymerase chain reaction with allele-specific hybridization. The activity of CYP2D6 was evaluated by determining the concentration of endogenous substrate of the enzyme and its urinary metabolite — pinoline to 6-hydroxy-1,2,3,4-tetrahydro-beta-carboline ratio, using high-performance liquid chromatography – mass spectrometry. The statistically significant differences between the scores on the Hamilton Depression Rating Scale (HAMD) in patients with different genotypes were revealed by day 16: (GG) 5.0 [3.0; 6.0], (GA) 1.5 [1.0; 3.2] (p < 0.001), and for the The UKU Side Effects Rating Scale (UKU): (GG) 6.0 [6.0; 7.0], (GA) 8.5 [8.0; 10.0] (p < 0.001). The calculation of correlation coefficients between the differences in scale scores and metabolic rate showed the presence of statistically significant weak inverse correlation with the efficacy indicator evaluated by HAMD (r = −0.278, p < 0.05), but not by UKU (r = 0.274, p > 0.05). This study demonstrated that an increased CYP2D6 activity reduces the efficacy of treatment with mirtazapine.

Download Full-text